Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02944383 · ClinicalTrials.gov registry record · Phase 2
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A Phase 2 study, sponsored by NeuroBo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT02944383 is a Phase 2 study that has completed, run by NeuroBo Pharmaceuticals. The registered enrollment target is 91 participants.
The verdict
NCT02944383, a Phase 2 study, has completed, sponsored by NeuroBo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
Interventions
- DRUG Placebo
- DRUG Gemcabene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02944383
The ClinicalTrials.gov registry entry for NCT02944383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroBo Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02944383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02944383 about?
NCT02944383 is a clinical study titled "A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia". A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
What is the current status of trial NCT02944383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2016-12. Estimated completion is 2018-05-09.
What interventions are being tested in trial NCT02944383?
The interventions under investigation include: Placebo (DRUG), Gemcabene (DRUG).
Who is sponsoring clinical trial NCT02944383?
This trial is sponsored by NeuroBo Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.